{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-006608","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.870744+00:00","generated_at":"2026-06-01T16:55:23.661851+00:00","sec_items":["1.01","3.02","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dermata raises $2.66M via immediate exercise of warrants at reduced price; issues new warrants","bullets":["Exercise of 516,336 warrants at reduced exercise price of $5.16 per share for cash gross proceeds of ~$2.66M.","Issues new Series A warrants for 601,174 shares (exercise price $4.91, 5.5-year term) and Series B warrants for 431,498 shares (exercise price $4.91, 24-month term).","H.C. Wainwright acts as placement agent; receives 7% cash fee plus 36,144 placement agent warrants at $6.45 exercise price.","Net proceeds for general corporate purposes including R&D, clinical trials, and working capital.","Closing expected on or about May 21, 2024; resale registration statement to be filed for new warrant shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-006608","json":"https://secwatch.observer/filing/0001654954-24-006608.json","markdown":"https://secwatch.observer/filing/0001654954-24-006608.md","text":"https://secwatch.observer/filing/0001654954-24-006608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006608/0001654954-24-006608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006608/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T16:55:23.661851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5d0395accd467e01d5af418a91f7087bfae64da","claim":"Dermata Therapeutics, Inc. entered into Inducement Letter with holders of Existing Warrants valued at aggregate gross proceeds of approximately $2.66 million (effective 2024-05-17).","evidence_excerpt":"On May 17, 2024, Dermata Therapeutics, Inc. (the “ Company ”) entered into inducement offer letter agreements (each, an “ Inducement Letter ”) with holders (the “ Holders ”) of certain of the Company's existing warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006608/0001654954-24-006608-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"holders of Existing Warrants"},{"label":"Value","value":"aggregate gross proceeds of approximately $2.66 million"},{"label":"Effective","value":"2024-05-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}